Block listing Interim Review
01 June 2018 15:00 BST
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 1 June 2018
|Name of applicant:||ASTRAZENECA PLC|
|Name of scheme:||ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME|
|Period of return:||From:||1 December 2017||To:||31 May 2018|
|Balance of unallotted securities under scheme(s) from previous return:||2,657,192|
|Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):||0|
|Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):||665,884|
|Equals: Balance under scheme(s) not yet issued/allotted at end of period:||1,991,308|
|Name of contact:||CAMILLA WISEMAN|
|Telephone number of contact:||020 3749 5000|
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
|Gonzalo Viña||UK/Global||+44 203 749 5916|
|Rob Skelding||UK/Global||+44 203 749 5821|
|Matt Kent||UK/Global||+44 203 749 5906|
|Karen Birmingham||UK/Global||+44 203 749 5634|
|Jacob Lund||Sweden||+46 8 553 260 20|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||+44 203 749 5712|
|Josie Afolabi||+44 7970 620 449|
|Craig Marks||Finance; Fixed Income; M&A||+44 7881 615 764|
|Henry Wheeler||Oncology||+44 203 749 5797|
|Mitchell Chan||Oncology; Other||+1 240 477 3771|
|Christer Gruvris||Brilinta; Diabetes||+44 203 749 5711|
|Nick Stone||Respiratory; Renal||+44 203 749 5716|
|Jennifer Kretzmann||Retail investors||+44 203 749 5824|
|US toll free||+1 866 381 7277|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.